Statements (34)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
antimuscarinic agent |
| gptkbp:approvedBy |
gptkb:Germany
|
| gptkbp:ATCCode |
gptkb:G04BD09
|
| gptkbp:bioavailability |
10%
|
| gptkbp:CASNumber |
10405-02-4
|
| gptkbp:contraindication |
urinary retention
uncontrolled narrow-angle glaucoma gastric retention |
| gptkbp:discoveredBy |
gptkb:Dr._Karl_Thomae_GmbH
|
| gptkbp:eliminationHalfLife |
20 hours
|
| gptkbp:excretion |
urine
|
| gptkbp:hasMolecularFormula |
C25H30ClNO3
|
| https://www.w3.org/2000/01/rdf-schema#label |
trospium chloride
|
| gptkbp:legalStatus |
prescription only
|
| gptkbp:mechanismOfAction |
muscarinic receptor antagonist
|
| gptkbp:metabolism |
liver
|
| gptkbp:pregnancyCategory |
C (US)
|
| gptkbp:proteinBinding |
50-85%
|
| gptkbp:routeOfAdministration |
oral
|
| gptkbp:sideEffect |
constipation
headache blurred vision dry mouth dyspepsia |
| gptkbp:synonym |
gptkb:Regurin
gptkb:Sanctura Spasmex |
| gptkbp:usedFor |
urinary incontinence
overactive bladder urinary frequency urinary urgency |
| gptkbp:bfsParent |
gptkb:trospium
|
| gptkbp:bfsLayer |
7
|